Vamil Divan
Stock Analyst at Guggenheim
(4.83)
# 79
Out of 5,090 analysts
242
Total ratings
67.05%
Success rate
22.67%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Buy | $33 → $35 | $25.70 | +36.19% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $12.52 | +35.84% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.60 | +401.57% | 1 | Nov 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $114 → $115 | $82.13 | +40.03% | 13 | Nov 10, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.67 | +348.97% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $228.71 | +5.81% | 28 | Oct 20, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $167 → $206 | $202.48 | +1.74% | 17 | Sep 23, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $6.38 | +72.55% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $8.73 | +48.91% | 2 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Buy | $125 → $172 | $205.04 | -16.11% | 7 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $35.64 | +9.43% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.58 | +171.32% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $340.33 | -15.38% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $6.54 | +817.43% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $100.89 | +13.99% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $35.39 | +32.81% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.68 | +172.11% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $42.61 | +43.16% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $20.24 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $3.96 | +556.57% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.38 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $26.59 | -28.53% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $153.75 | -36.26% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.30 | +16.06% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.60 | +285.36% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $148.41 | -66.98% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,014.49 | -64.91% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.72 | -10.65% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $9.61 | +1,502.50% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.80 | +120.75% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.82 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $28.41 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $8.85 | +69.59% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $51.95 | +17.42% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.81 | +2,603.41% | 3 | Jan 17, 2018 |
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $25.70
Upside: +36.19%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $12.52
Upside: +35.84%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.60
Upside: +401.57%
ANI Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $114 → $115
Current: $82.13
Upside: +40.03%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.67
Upside: +348.97%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $228.71
Upside: +5.81%
Johnson & Johnson
Sep 23, 2025
Upgrades: Buy
Price Target: $167 → $206
Current: $202.48
Upside: +1.74%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.38
Upside: +72.55%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $8.73
Upside: +48.91%
Insmed
Sep 8, 2025
Maintains: Buy
Price Target: $125 → $172
Current: $205.04
Upside: -16.11%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $35.64
Upside: +9.43%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.58
Upside: +171.32%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $340.33
Upside: -15.38%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.54
Upside: +817.43%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $100.89
Upside: +13.99%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $35.39
Upside: +32.81%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.68
Upside: +172.11%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $42.61
Upside: +43.16%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $20.24
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $3.96
Upside: +556.57%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $3.38
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $26.59
Upside: -28.53%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $153.75
Upside: -36.26%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.30
Upside: +16.06%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.60
Upside: +285.36%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $148.41
Upside: -66.98%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,014.49
Upside: -64.91%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.72
Upside: -10.65%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $9.61
Upside: +1,502.50%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.80
Upside: +120.75%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $31.82
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $28.41
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $8.85
Upside: +69.59%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $51.95
Upside: +17.42%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.81
Upside: +2,603.41%